Dr. Dorothy Auth has more than 20 years of experience in complex patent litigation, as well as licensing, patent procurement, and intellectual property counseling in the United States and abroad. Her experience spans diverse industries, including biotechnology, pharmaceutical, and medical devices, as well as consumer products, computers, and other mechanical devices.
Dorothy addresses intellectual property diligence issues surrounding mergers, acquisitions, and bankruptcies. Representative clients in transactional IP matters includes the U.S. Treasury, Salix Pharmaceuticals, Ltd., Pfizer; Elan Pharmaceutical, Healthcare Royalty Partners; Fountanbleu Hotel; Quart Rx Pharma; iShares; Towers Watson; Hess and Triarco. In the transactional area, Dorothy advises clients on the validity of target patents as well as performing clearance analysis on the patents of competitors to render freedom-to-operate opinions.
Dorothy also litigates in U.S. Federal Courts and in international arbitrations conducted under the WIPO rules. She conducts all aspects of litigation, including motion practice, expert preparation and all aspects of discovery practice. Representative litigation clients include Medinol, DuPont, Osteonics, and Kanzaki.
Dorothy also coordinates global patent procurement and enforcement strategies for her clients to maximize their patent-protected field. In this area, Dorothy's practice includes U.S. and international client counseling regarding IP matters. Her international experience includes coordinating patent infringement trials and hearings as between the U.S. and different European jurisdictions including trials seeking preliminary relief and cross-border injunctions, as well as nullity, cancellation, and oppositions proceedings on patent rights.
Among the clients Dorothy has counseled are Credit Suisse, Rhone-Poulenc Rohrer, Inc., BioRest Ltd., Oscillon Ltd., Digene Corporation, Hoffmann-La Roche, and the National Institutes of Health.
At the firm, Dorothy is the Partner Chair of the Women's Leadership Initiative. In addition, Dorothy is a member of the Technology Committee, the Healthcare Industry Team and the Advisory Counsel for the firm's Center for Career Advancement.
Dorothy is the President Elect of the New York Intellectual Property Law Association as well as the Board Liaison to the Strategic Planning Committee and the Women in IP Law Committee. She is also a member of the American Intellectual Property Association and the Intellectual Property Owner's Association.
Dorothy is a frequent speaker on a wide variety of topics including:
•Update in Reverse Payment Settlements after Actavis
•Post Grant Review and Inter Partes Proceedings
•Annual Update in Biotech/Pharama Patent Law - PLI
•Patent Eligibility under 101 for Biotechnology
Prior to joining Cadwalader, she was a partner with Morgan & Finnegan, an intellectual property specialty firm in New York.
Dorothy earned her J.D. from St. John's School of Law, a Ph.D. in biochemistry from Tufts Medical School, and her B.A. in biochemistry from Cook College of Rutgers University.
Dorothy is admitted to practice in New York and New Jersey and before the U.S. District Courts for the Southern and Eastern Districts of New York and the District of New Jersey, and the U.S. Courts of Appeals for the Second and Federal Circuits. She is also licensed to practice before the U.S. Patent and Trademark Office.
News & Resources
•Cadwalader Represents Salix Pharmaceuticals in Its Pending Acquisition by Valeant Pharmaceuticals Feb 22, 2015
•New Deals - Lawyers on Major Transactions Jan 29, 2009
Clients & Friends Memos
•New Decision Increases Calculation of Patent Term Jan 16, 2014
•Final Patent Rules Quell Jitters Over Post-Grant Proceedings Oct 11, 2012
•NJIPLA & NYIPLA Joint Program: Intellectual Property Protection in China from A-Z Feb 12, 2015
International Trade Commission
•ITC Proposed New Procedures for Electronic FilingSep 26, 2011
•VS.: Interview with FBI Anti-trafficking Unit Dec 11, 2012